A dog model for centronuclear myopathy carrying the most common DNM2 mutation.


Journal

Disease models & mechanisms
ISSN: 1754-8411
Titre abrégé: Dis Model Mech
Pays: England
ID NLM: 101483332

Informations de publication

Date de publication:
01 04 2022
Historique:
received: 28 07 2021
accepted: 21 02 2022
pubmed: 5 3 2022
medline: 16 4 2022
entrez: 4 3 2022
Statut: ppublish

Résumé

Mutations in DNM2 cause autosomal dominant centronuclear myopathy (ADCNM), a rare disease characterized by skeletal muscle weakness and structural anomalies of the myofibres, including nuclear centralization and mitochondrial mispositioning. Following the clinical report of a Border Collie male with exercise intolerance and histopathological hallmarks of CNM on the muscle biopsy, we identified the c.1393C>T (R465W) mutation in DNM2, corresponding to the most common ADCNM mutation in humans. In order to establish a large animal model for longitudinal and preclinical studies on the muscle disorder, we collected sperm samples from the Border Collie male and generated a dog cohort for subsequent clinical, genetic and histological investigations. Four of the five offspring carried the DNM2 mutation and showed muscle atrophy and a mildly impaired gait. Morphological examinations of transverse muscle sections revealed CNM-typical fibres with centralized nuclei and remodelling of the mitochondrial network. Overall, the DNM2-CNM dog represents a faithful animal model for the human disorder, allows the investigation of ADCNM disease progression, and constitutes a valuable complementary tool to validate innovative therapies established in mice.

Identifiants

pubmed: 35244154
pii: 274622
doi: 10.1242/dmm.049219
pmc: PMC9016898
pii:
doi:

Substances chimiques

DNM2 protein, human EC 3.6.5.5
Dynamin II EC 3.6.5.5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2022. Published by The Company of Biologists Ltd.

Déclaration de conflit d'intérêts

Competing interests J.L. is co-founder of Dynacure.

Références

J Neuromuscul Dis. 2015 Jun 4;2(2):167-174
pubmed: 27858727
BMC Neurol. 2015 Oct 30;15:223
pubmed: 26517984
EMBO J. 2016 Nov 2;35(21):2270-2284
pubmed: 27670760
EMBO J. 2010 Nov 3;29(21):3593-606
pubmed: 20935625
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14697-702
pubmed: 20682747
Skelet Muscle. 2019 May 27;9(1):15
pubmed: 31133066
Front Vet Sci. 2020 Mar 11;7:80
pubmed: 32219101
PLoS Genet. 2013 Jun;9(6):e1003430
pubmed: 23754947
Nat Genet. 2005 Mar;37(3):289-94
pubmed: 15731758
Neuromuscul Disord. 2020 May;30(5):353-359
pubmed: 32417001
Clin Immunol. 2001 Feb;98(2):235-43
pubmed: 11161980
Skelet Muscle. 2015 Jan 27;5(1):1
pubmed: 25664165
Hum Mol Genet. 2010 Dec 15;19(24):4820-36
pubmed: 20858595
Nature. 2011 Sep 18;477(7366):556-60
pubmed: 21927000
Sci Transl Med. 2014 Jan 22;6(220):220ra10
pubmed: 24452262
Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):11066-11071
pubmed: 30291191
Hum Mol Genet. 2019 Dec 15;28(24):4067-4077
pubmed: 31628461
Nat Genet. 1996 Jun;13(2):175-82
pubmed: 8640223
Hum Mol Genet. 2008 Jul 15;17(14):2132-43
pubmed: 18434328
Neuromuscul Disord. 2009 Nov;19(11):788-96
pubmed: 19800232
Nat Genet. 2005 Nov;37(11):1207-9
pubmed: 16227997
Genet Mol Biol. 2015 May;38(2):147-51
pubmed: 26273216
Nat Rev Mol Cell Biol. 2012 Jan 11;13(2):75-88
pubmed: 22233676
Hum Mol Genet. 2005 Jun 1;14(11):1417-27
pubmed: 15829503
Mol Biol Cell. 2009 Aug;20(15):3561-71
pubmed: 19515832
Nat Genet. 2007 Sep;39(9):1134-9
pubmed: 17676042
J Biol Chem. 2010 Jul 23;285(30):22753-7
pubmed: 20529869
Brain. 2014 Dec;137(Pt 12):3160-70
pubmed: 25260562
Mol Ther. 2012 Nov;20(11):2120-33
pubmed: 22968479
Hum Mutat. 2012 Jun;33(6):949-59
pubmed: 22396310
J Small Anim Pract. 2012 Oct;53(10):608-12
pubmed: 23013377
Nature. 2005 Dec 1;438(7068):590-6
pubmed: 16319878
J Gene Med. 2011 Sep;13(9):497-506
pubmed: 22144143
Mol Biol Cell. 1997 Dec;8(12):2553-62
pubmed: 9398675
J Neuromuscul Dis. 2019;6(4):421-451
pubmed: 31450509
Science. 2018 Oct 5;362(6410):86-91
pubmed: 30166439

Auteurs

Johann Böhm (J)

Médecine translationnelle et neurogénétique, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Inserm U 1258, CNRS UMR 7104, Université de Strasbourg, 67404 Illkirch, France.

Inès Barthélémy (I)

Neuroscience et psychiatrie, Université Paris-Est Créteil, INSERM, IMRB, 94010 Créteil, France.
Ecole nationale vétérinaire d'Alfort, IMRB, 94700 Maisons-Alfort, France.
EFS, IMRB, 94017 Créteil Cedex, France.

Charlène Landwerlin (C)

Médecine translationnelle et neurogénétique, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Inserm U 1258, CNRS UMR 7104, Université de Strasbourg, 67404 Illkirch, France.

Nicolas Blanchard-Gutton (N)

Neuroscience et psychiatrie, Université Paris-Est Créteil, INSERM, IMRB, 94010 Créteil, France.
Ecole nationale vétérinaire d'Alfort, IMRB, 94700 Maisons-Alfort, France.
EFS, IMRB, 94017 Créteil Cedex, France.

Frédéric Relaix (F)

Neuroscience et psychiatrie, Université Paris-Est Créteil, INSERM, IMRB, 94010 Créteil, France.
Ecole nationale vétérinaire d'Alfort, IMRB, 94700 Maisons-Alfort, France.
EFS, IMRB, 94017 Créteil Cedex, France.

Stéphane Blot (S)

Neuroscience et psychiatrie, Université Paris-Est Créteil, INSERM, IMRB, 94010 Créteil, France.
Ecole nationale vétérinaire d'Alfort, IMRB, 94700 Maisons-Alfort, France.
EFS, IMRB, 94017 Créteil Cedex, France.

Jocelyn Laporte (J)

Médecine translationnelle et neurogénétique, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Inserm U 1258, CNRS UMR 7104, Université de Strasbourg, 67404 Illkirch, France.

Laurent Tiret (L)

Neuroscience et psychiatrie, Université Paris-Est Créteil, INSERM, IMRB, 94010 Créteil, France.
Ecole nationale vétérinaire d'Alfort, IMRB, 94700 Maisons-Alfort, France.
EFS, IMRB, 94017 Créteil Cedex, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH